Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Net Cash Provided by (Used in) Operating Activities
Net Income (Loss)	$ 11,738,488	$ 10,054,654
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities
Depreciation and amortization of plant, property and equipment	1,300,651	746,931
Amortization of intangible assets	1,282,495	1,098,757
Amortization of prepaid lease	884,950	923,380
Stock-based compensation	0	123,135
Deferred taxes	339,358	(319,501)
Loss on disposal of property, plant and equipment	0	184,262
Gain on disposal of acer truncatum bunge plants	(642,532)	0
Impairment of assets	332,090	986,406
Changes in operating assets and liabilities:
Change in purchase deposit to vendors	677,695	(667,291)
Change in inventory	3,447,670	(3,425,678)
Change in accounts receivable	1,016,216	(651,680)
Cash received from cancellation of lease	57,858	0
Change in taxes payable	(1,007,109)	1,369,927
Change in security deposit to related party	0	(1,486,171)
Change in purchase deposit and accounts payable to related party, net	(2,076,172)	663,222
Change in advance from customers	423,132	0
Increase (Decrease) in Accounts Payable and Accrued Liabilities	92,108	135,721
Net Cash Provided by (Used in) Operating Activities, Continuing Operations	17,866,898	9,736,074
Net Cash Provided by (Used in) Investing Activities
Acquisition of property, plant and equipment	(2,153,063)	(2,880,051)
Proceeds from disposal of acer truncatum bunge plants	2,156,510	0
Development cost of acer truncatum bunge planting	(4,542,518)	(3,618,469)
Net Cash Provided by (Used in) Investing Activities	(4,539,071)	(6,498,520)
Effect of exchange rate changes on cash and cash equivalents	1,716,911	(568,016)
Cash and Cash Equivalents, Period Increase (Decrease)	15,044,738	2,669,538
Cash and Cash Equivalents, at Carrying Value, Beginning Balance	10,308,622	7,639,084
Cash and Cash Equivalents, at Carrying Value, Ending Balance	25,353,360	10,308,622
Supplemental Cash Flow Information
Interest Paid, Including Capitalized Interest, Operating and Investing Activities	0	0
Income Taxes Paid, Net	4,445,597	2,521,061
Cash Flow, Noncash Investing and Financing Activities Disclosure
Transfer 3% equity of Shandong Spring Pharmaceutical in exchange for equipment and intangible assets	$ 0	$ 2,134,537